Jefferies Global Healthcare Conference in London - SAB BIOTHERAPEUTICS INC
Explicit Guidance:
- Clinical Data Release: Top-line data from the pivotal Phase 2b "SAVEGUARD" study expected in 2027; data release timeline for Phase 3 "PRIZE" study currently undefined pending enrollment pace but anticipated to follow first patient enrollment in the current quarter.
- Regulatory Milestones: Anticipates filing a Biologics License Application (BLA) for market registration immediately following positive top-line results from the SAVEGUARD study (estimated 2027).
- Market Opportunity: Management anticipates a $20 billion total addressable market (TAM) for Type 1 Diabetes (T1D) as a disease-modifying autoimmunity indication, noting current market penetration is in early stages.
Business-Segment Outlook:
- Product Portfolio:
- SAB-142 (Human Antithymocyte Immunoglobulin): Positioned as a superior second-comer to T-Zield. Expected to demonstrate efficacy in preserving C-peptide (primary endpoint) and improving HbA1c, reducing insulin use, decreasing hypoglycemic events, and improving "time in range" (secondary endpoints) via continuous glucose monitoring.
- Target Product Profile: Differentiates from competitors with a 2-day dosing regimen (vs. 12-day for T-Zield), redosability for chronic disease management (vs. T-Zield's one-time infusion), and a fully human composition to avoid serum sickness.
- Study Expansion (PRIZE Study): A Phase 3 investigator-initiated study will expand the eligible patient window from the standard 100 days post-diagnosis to up to two years (Cohort 2: 100–365 days; Cohort 3: 365 days–2 years). Positive results here are expected to expand the commercial label and market access.
- Enrollment Metrics: PRIZE study targets enrollment of 72 new patients across 7 sites; first patient enrolled in the current quarter.
- Product Portfolio:
Market and Competitive Outlook:
- Competitive Landscape: Acknowledges T-Zield's recent FDA approval and its role in educating the medical community on C-peptide preservation. Expects a "strong second-comer advantage" for SAB-142 driven by superior convenience and efficacy.
- Competitor Performance: Notes T-Zield's Stage 3 first-quarter sales reached approximately $47 million (vs. $25 million plateau in Stage 2), indicating strong market acceptance despite the 12-day dosing burden.
- Market Share Dynamics: Anticipates capturing significant market share as the industry shifts from "insulin management" to "organ preservation," with SAB-142 positioned to capture patients outside the narrow 100-day window of competitors.
Macro / Industry Outlook:
- Disease Paradigm Shift: Foresees a structural shift in the T1D treatment landscape toward immunomodulation and disease-modifying therapies aimed at preserving endogenous insulin production, moving beyond traditional insulin delivery and glucose monitoring.
- Commercialization Timeline: The company views the current period as "early days" for the T1D autoimmunity sector, with growing investor and pharma interest following the 2024 approval of T-Zield.
- Pricing/Reimbursement: While not explicitly stating future pricing, management anticipates that achieving full approval (via secondary endpoints) rather than accelerated approval (C-peptide only) will provide a "massive value inflection point" for a pre-commercial company.
Strategic Initiatives:
- Pivotal Trial Execution: Finalizing enrollment for the SAVEGUARD study this month; trial design modeled after the "TN-19" study (using thymoglobulin historical data) to ensure statistical power for both C-peptide and HbA1c endpoints.
- Pipeline Expansion: Advancing the PRIZE study to validate treatment efficacy up to two years post-diagnosis, aiming to broaden the label eligibility and address patient/advocate concerns regarding arbitrary time-from-diagnosis restrictions.
- Regulatory Strategy: Prepared to pursue accelerated approval based on C-peptide preservation alone if secondary endpoints are not met in SAVEGUARD, with a pre-planned strategy to conduct additional trials to satisfy full approval requirements.
Risks and Headwinds to Outlook:
- Trial Uncertainty: While confidence is high based on historical data from thymoglobulin, there is a risk that the study may only hit the primary C-peptide endpoint, necessitating further trials for full approval.
- Enrollment Variability: Control over the PRIZE study timeline is limited as it is run by academic investigators; enrollment pace could delay data availability.
- Competitive Headwinds: T-Zield's dominance in establishing the category could initially overshadow SAB-142, though management argues their dosing and redosability advantages will secure adoption.
- Safety Concerns: Anticipated adverse events include infusion-related reactions, headaches, and Grade 1 CRS (flu-like symptoms with fever), which are expected to be manageable but must be monitored.
Management Tone on the Future:
- Confidence Level: High confidence ("high confidence in our likelihood of success") regarding the ability to hit secondary endpoints (HbA1c) due to the study design mirroring the successful thymoglobulin trials.
- Strategic Optimism: Expresses strong conviction that SAB-142 offers a "superior product" for preserving insulin production and will "transform what it means to have T1D."
- Differentiation Focus: Emphasizes a clear competitive moat (2-day vs. 12-day dosing, redosability, human vs. rabbit protein) as the key driver for market adoption.
Miscellaneous:
- Target Patient Profile: Focus on newly diagnosed patients; SAVEGUARD covers patients within the first 100 days of diagnosis, while PRIZE targets those diagnosed up to 2 years prior.
- Data Measurement: All patients in the SAVEGUARD trial are required to use continuous glucose monitoring to accurately measure "time in range" and insulin use trends.
- Company
- SAB BIOTHERAPEUTICS INC
- Keywords
- SAB BIOTHERAPEUTICS INC